Developer docs
API playgroundTry for free, no card

Search company profiles

Swarm Oncology

Full company profile

uuid00278ix

Namestring
Swarm Oncology
Legal namestring
Swarm Oncology Limited
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Swarm Oncology is a UK-based clinical-stage biotechnology company founded in 2022 that develops personalized T cell therapies for patients with advanced and metastatic solid cancers. The company operates from registered offices in London (at the Delin Ventures address) and runs its primary R&D laboratories across two University of Glasgow sites — the Sir Graeme Davies Building and the Clinical Innovation Zone at Queen Elizabeth University Hospital. Its stated customer segment is patients with metastatic solid tumours, where 82.4% of patients die from their disease, and where existing immunotherapies are limited by toxicity, inefficacy in solid tumours, and reliance on pre-existing immune responses.

The company's core product is Swarm-T, an autologous antigen-specific T cell therapy manufactured from patients who have received personalized cancer vaccinations. The platform combines in vivo priming (a vaccine that primes tumour-antigen-specific T cells) with a proprietary T cell isolation process that discards non-effective immune cells and enriches the fittest antigen-specific T cells from peripheral blood. The resulting cell product is described as phenotypically optimized, cost-efficient, and durable. The lead pipeline candidate, SWM-XXX, targets multiple solid tumour types and is positioned at preclinical / pre-IND development. Swarm has completed GMP technology transfer to Cellex Cell Professionals GmbH, which holds German Manufacturer's Authorisation for clinical-grade drug product manufacturing, de-risking first-in-human supply.

Swarm Oncology is pre-revenue and pre-commercial. Its revenue model contemplates one-time licensing of cell therapy products upon regulatory approval and commercialization, with pricing not publicly disclosed and typical of value-based cell therapy negotiations. Go-to-market is enterprise-focused, relying on research collaborations with leading hospitals (including a US hospital partnership for patient sample analysis and platform validation) and on CDMO partnerships for manufacturing. The company is funded by Delin Ventures via an extended £6.1M seed round (March 2026) and is led by CEO Martin Olin, CSO Prof. John Campbell, COO Shree Patel, and Chairman Bernhard Ehmer, with a broad scientific and clinical advisory board.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
adoptive cell therapy, T cell immunotherapy, solid tumor treatment, personalized cancer vaccines, autologous cell therapy
Industry3 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
T Cell Immunotherapy / Cell Therapy
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1T Cell Therapy Products
TypeOne Time License
Description

Autologous antigen-specific T cell adoptive therapies for solid organ cancers. Revenue will be generated from clinical-stage cell therapy products once approved and commercialized.

swarmoncology.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Swarm Oncology develops personalized autologous antigen-specific T cell therapies for patients with advanced and metastatic solid cancers. Its Swarm-T product is manufactured from patients who have received personalized cancer vaccinations, isolating and expanding tumour-targeting T cells that are phenotypically optimized, cost efficient, and durable. The Swarm T Cell Therapy Platform combines in vivo priming, antigen-specific T cell isolation, and GMP-compliant manufacturing, with lead pipeline candidate SWM-XXX progressing through preclinical and Phase I development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Swarm Oncology is a biotechnology company developing personalised T cell therapies for advanced solid cancers. The company's core offering is the Swarm-T product, an autologous antigen-specific T cell therapy that works in combination with in vivo priming (personalised cancer vaccines). The Swarm T Cell Therapy Platform enables the isolation, expansion, and manufacturing of potent, early memory T cells that are highly targeted and durable. The lead pipeline candidate is SWM-XXX for multiple solid tumour types. The platform is designed to improve upon existing immunotherapy approaches by generating a powerful, sustained cellular immune attack on advanced solid cancers.

Product and service3 records
1Swarm-T
CategoryCell therapy product
Description

An autologous antigen-specific T cell therapy product manufactured from patients who have received personalised cancer vaccinations. The therapy isolates and expands tumour-targeting T cells that are phenotypically optimized, cost efficient, and durable, intended for treatment of advanced solid cancers.

2Swarm T Cell Therapy Platform
CategoryCell therapy platform
Description

A technology platform designed to unlock the full potential of personalised T cell therapies through a combination of in vivo priming, antigen-specific T cell isolation, and product manufacturing capabilities. The platform delivers cell therapies that are highly targeted, phenotypically optimized, cost efficient, and durable, with completed GMP technology transfer to a CDMO enabling clinical-grade manufacturing.

3SWM-XXX
CategoryPipeline candidate
Description

Lead pipeline candidate of Swarm Oncology targeting multiple solid tumour types, currently in preclinical/Pre-IND/Phase I development stages as an autologous antigen-specific T cell therapy for advanced solid cancers.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-05
Description

Swarm Oncology completed GMP technology transfer to Cellex Cell Professionals GmbH, which has received German Manufacturer's Authorisation enabling GMP-compliant production for clinical trials. This partnership enables Swarm to manufacture clinical-grade drug products for first-in-human studies.

2Leading US Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

Research collaboration with a leading US hospital to enhance the manufacturing and efficacy of T cell therapies for solid cancers. The collaboration involves analyzing patient samples to validate their platform that aims to improve cancer vaccine outcomes. Includes immune profiling and research-scale manufacturing of personalized T-cell treatments.

globenewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Turnstone Biologics
TypeDirect peer
Description

Clinical-stage biotech developing tumor-infiltrating lymphocyte (TIL) and selected T cell therapies for solid tumors. Comparable autologous T cell platform targeting advanced solid cancers.

TypeDirect peer
Description

Personalized TCR-T cell therapy developer for solid tumors (acquired by AstraZeneca). Closely comparable in approach — isolating and engineering tumor-specific TCRs from patient T cells for autologous therapy.

TypeDirect peer
Description

UK-based clinical-stage biotech developing personalized neoantigen-targeted T cell therapies for solid tumors. Closest direct peer given Swarm's autologous, patient-specific T cell platform targeting solid cancers.

TypeBroad incumbent
Description

Major mRNA biotech developing personalized cancer vaccines (mRNA-4157/V940) in partnership with Merck. Indirectly comparable — success of Moderna's personalized vaccines would validate the in vivo priming concept Swarm depends on.

TypeDirect peer
Description

UK-based biotech developing TCR-based immunotherapies (ImmTAC platform) for solid tumors and infectious disease. Comparable as a T cell receptor-based oncology company targeting solid tumor antigens.

TypeDirect peer
Description

Clinical-stage biotech developing TCR-based immunotherapies and adoptive cell therapies for solid tumors. Directly comparable in targeting tumor-specific antigens via T cell approaches.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered TCR-T cell therapies for solid tumors. Directly comparable in modality (T cell therapy, solid tumor focus) though using engineered receptors versus Swarm's naturally primed T cells.

TypeBroad incumbent
Description

Large biotech with leading personalized neoantigen cancer vaccine programs (BNT122) and a growing cell therapy pipeline. Comparable as a personalized cancer immunotherapy incumbent whose vaccine approach underpins Swarm's in vivo priming strategy.

TypeDirect peer
Description

Commercial-stage cell therapy company with the first FDA-approved TIL therapy (lifileucel) for melanoma. Comparable as an autologous adoptive T cell therapy developer for solid tumors with proven manufacturing scale.

TypeDirect peer
Description

Clinical-stage cell therapy company focused on engineering T cells for solid tumors with enhanced persistence and resistance to exhaustion. Comparable autologous T cell therapy approach with solid tumor focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Swarm Oncology

T Cell Immunotherapy / Cell Therapyswarmoncology.bio

What Swarm Oncology does

Swarm Oncology is a UK-based clinical-stage biotechnology company founded in 2022 that develops personalized T cell therapies for patients with advanced and metastatic solid cancers. The company operates from registered offices in London (at the Delin Ventures address) and runs its primary R&D laboratories across two University of Glasgow sites — the Sir Graeme Davies Building and the Clinical Innovation Zone at Queen Elizabeth University Hospital. Its stated customer segment is patients with metastatic solid tumours, where 82.4% of patients die from their disease, and where existing immunotherapies are limited by toxicity, inefficacy in solid tumours, and reliance on pre-existing immune responses.

The company's core product is Swarm-T, an autologous antigen-specific T cell therapy manufactured from patients who have received personalized cancer vaccinations. The platform combines in vivo priming (a vaccine that primes tumour-antigen-specific T cells) with a proprietary T cell isolation process that discards non-effective immune cells and enriches the fittest antigen-specific T cells from peripheral blood. The resulting cell product is described as phenotypically optimized, cost-efficient, and durable. The lead pipeline candidate, SWM-XXX, targets multiple solid tumour types and is positioned at preclinical / pre-IND development. Swarm has completed GMP technology transfer to Cellex Cell Professionals GmbH, which holds German Manufacturer's Authorisation for clinical-grade drug product manufacturing, de-risking first-in-human supply.

Swarm Oncology is pre-revenue and pre-commercial. Its revenue model contemplates one-time licensing of cell therapy products upon regulatory approval and commercialization, with pricing not publicly disclosed and typical of value-based cell therapy negotiations. Go-to-market is enterprise-focused, relying on research collaborations with leading hospitals (including a US hospital partnership for patient sample analysis and platform validation) and on CDMO partnerships for manufacturing. The company is funded by Delin Ventures via an extended £6.1M seed round (March 2026) and is led by CEO Martin Olin, CSO Prof. John Campbell, COO Shree Patel, and Chairman Bernhard Ehmer, with a broad scientific and clinical advisory board.

Swarm Oncology firmographics

Firmographics
Name
Swarm Oncology
Legal name
Swarm Oncology Limited
Website
https://swarmoncology.bio
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Swarm Oncology industry classification

Industry
Product category
T Cell Immunotherapy / Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Adoptive cell therapy
  • T cell immunotherapy
  • Solid tumor treatment
  • Personalized cancer vaccines
  • Autologous cell therapy

Where Swarm Oncology is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Swarm Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. T Cell Therapy Products: Autologous antigen-specific T cell adoptive therapies for solid organ cancers. Revenue will be generated from clinical-stage cell therapy products once approved and commercialized.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Swarm Oncology product offering

Product offering

Core offering

Swarm Oncology develops personalized autologous antigen-specific T cell therapies for patients with advanced and metastatic solid cancers. Its Swarm-T product is manufactured from patients who have received personalized cancer vaccinations, isolating and expanding tumour-targeting T cells that are phenotypically optimized, cost efficient, and durable. The Swarm T Cell Therapy Platform combines in vivo priming, antigen-specific T cell isolation, and GMP-compliant manufacturing, with lead pipeline candidate SWM-XXX progressing through preclinical and Phase I development.

Product overview

Swarm Oncology is a biotechnology company developing personalised T cell therapies for advanced solid cancers. The company's core offering is the Swarm-T product, an autologous antigen-specific T cell therapy that works in combination with in vivo priming (personalised cancer vaccines). The Swarm T Cell Therapy Platform enables the isolation, expansion, and manufacturing of potent, early memory T cells that are highly targeted and durable. The lead pipeline candidate is SWM-XXX for multiple solid tumour types. The platform is designed to improve upon existing immunotherapy approaches by generating a powerful, sustained cellular immune attack on advanced solid cancers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Swarm-T An autologous antigen-specific T cell therapy product manufactured from patients who have received personalised cancer vaccinations. The therapy isolates and expands tumour-targeting T cells that are phenotypically optimized, cost efficient, and durable, intended for treatment of advanced solid cancers.
  • Swarm T Cell Therapy Platform A technology platform designed to unlock the full potential of personalised T cell therapies through a combination of in vivo priming, antigen-specific T cell isolation, and product manufacturing capabilities. The platform delivers cell therapies that are highly targeted, phenotypically optimized, cost efficient, and durable, with completed GMP technology transfer to a CDMO enabling clinical-grade manufacturing.
  • SWM-XXX Lead pipeline candidate of Swarm Oncology targeting multiple solid tumour types, currently in preclinical/Pre-IND/Phase I development stages as an autologous antigen-specific T cell therapy for advanced solid cancers.

Companies that use Swarm Oncology

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Swarm Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Swarm Oncology partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Cellex Cell Professionals GmbHcoreTechnology or Integration · 5 March 2026Swarm Oncology completed GMP technology transfer to Cellex Cell Professionals GmbH, which has received German Manufacturer's Authorisation enabling GMP-compliant production for clinical trials. This partnership enables Swarm to manufacture clinical-grade drug products for first-in-human studies.
  • Leading US HospitalcoreStrategic or Co-development Partner · 28 October 2025Research collaboration with a leading US hospital to enhance the manufacturing and efficacy of T cell therapies for solid cancers. The collaboration involves analyzing patient samples to validate their platform that aims to improve cancer vaccine outcomes. Includes immune profiling and research-scale manufacturing of personalized T-cell treatments.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Swarm Oncology competitors and assessment

Company assessment

Direct peers

  • Turnstone Biologics: Clinical-stage biotech developing tumor-infiltrating lymphocyte (TIL) and selected T cell therapies for solid tumors. Comparable autologous T cell platform targeting advanced solid cancers.
  • Neogene Therapeutics: Personalized TCR-T cell therapy developer for solid tumors (acquired by AstraZeneca). Closely comparable in approach — isolating and engineering tumor-specific TCRs from patient T cells for autologous therapy.
  • Achilles Therapeutics: UK-based clinical-stage biotech developing personalized neoantigen-targeted T cell therapies for solid tumors. Closest direct peer given Swarm's autologous, patient-specific T cell platform targeting solid cancers.
  • Immunocore: UK-based biotech developing TCR-based immunotherapies (ImmTAC platform) for solid tumors and infectious disease. Comparable as a T cell receptor-based oncology company targeting solid tumor antigens.
  • Immatics: Clinical-stage biotech developing TCR-based immunotherapies and adoptive cell therapies for solid tumors. Directly comparable in targeting tumor-specific antigens via T cell approaches.
  • Adaptimmune: Clinical-stage cell therapy company developing engineered TCR-T cell therapies for solid tumors. Directly comparable in modality (T cell therapy, solid tumor focus) though using engineered receptors versus Swarm's naturally primed T cells.
  • Iovance Biotherapeutics: Commercial-stage cell therapy company with the first FDA-approved TIL therapy (lifileucel) for melanoma. Comparable as an autologous adoptive T cell therapy developer for solid tumors with proven manufacturing scale.
  • Lyell Immunopharma: Clinical-stage cell therapy company focused on engineering T cells for solid tumors with enhanced persistence and resistance to exhaustion. Comparable autologous T cell therapy approach with solid tumor focus.

Broad incumbents

  • Moderna: Major mRNA biotech developing personalized cancer vaccines (mRNA-4157/V940) in partnership with Merck. Indirectly comparable — success of Moderna's personalized vaccines would validate the in vivo priming concept Swarm depends on.
  • BioNTech: Large biotech with leading personalized neoantigen cancer vaccine programs (BNT122) and a growing cell therapy pipeline. Comparable as a personalized cancer immunotherapy incumbent whose vaccine approach underpins Swarm's in vivo priming strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Swarm Oncology compliance and trust

Trust signal

Compliance2 records

Swarm Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Swarm Oncology leadership team

Management profile

Number of profiles

Profiles18 records

Swarm Oncology funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Swarm Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swarm Oncology

What does Swarm Oncology do?

Swarm Oncology develops personalized autologous antigen-specific T cell therapies for patients with advanced and metastatic solid cancers. Its Swarm-T product is manufactured from patients who have received personalized cancer vaccinations, isolating and expanding tumour-targeting T cells that are phenotypically optimized, cost efficient, and durable. The Swarm T Cell Therapy Platform combines in vivo priming, antigen-specific T cell isolation, and GMP-compliant manufacturing, with lead pipeline candidate SWM-XXX progressing through preclinical and Phase I development.

Is Swarm Oncology a public or private company?

Swarm Oncology is a private company. It is classified as venture growth investor backed and is currently operating.

When was Swarm Oncology founded?

Swarm Oncology was founded in 2022. It employs 11 to 50 people.

Where is Swarm Oncology based?

Swarm Oncology is headquartered in London, United Kingdom, in the Europe region.

How does Swarm Oncology make money?

One revenue line is on record: T Cell Therapy Products.

Who are Swarm Oncology's main competitors?

Direct peers on record are Turnstone Biologics, Neogene Therapeutics, Achilles Therapeutics, Immunocore, Immatics, Adaptimmune, Iovance Biotherapeutics and Lyell Immunopharma. Broad incumbents are Moderna and BioNTech.

Does Swarm Oncology have an API?

No public API is recorded for Swarm Oncology.

What industry is Swarm Oncology in?

Swarm Oncology's product category is T Cell Immunotherapy / Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireSwarm Oncology appoints Bernhard Ehmer as ChairmanSwarm Oncology appointed Bernhard Ehmer as Chairman, coinciding with completion of GMP technology transfer to Cellex and a £6.1 million seed financing extension led by Delin Ventures. The company now has manufacturing readiness and capital to initiate its first-in-human study.SwarmoncologySwarm OncologySwarm Oncology has appointed Bernhard Ehmer, a veteran biotechnology executive with over three decades of oncology drug development experience, as Chairman of the Board of Directors. The company has simultaneously completed GMP technology transfer to Cellex Cell Professionals GmbH, which has received German Manufacturer's Authorisation, enabling GMP-compliant production for clinical trials. Additionally, Swarm Oncology has extended its seed financing round by £6.1 million, led by Delin Ventures, positioning the company to initiate its first-in-human clinical study for T cell therapies targeting advanced solid cancers.BioSpaceSwarm Oncology appoints Bernhard Ehmer as ChairmanSwarm Oncology appointed Bernhard Ehmer, a veteran biotechnology executive with extensive oncology drug development experience, as Chairman of the Board of Directors. The company simultaneously completed its GMP technology transfer to Cellex Cell Professionals GmbH, securing German Manufacturer's Authorisation for clinical-grade drug product manufacturing, and extended its seed financing round by £6.1 million led by Delin Ventures. These developments position the company to initiate its first-in-human clinical study for its T cell therapy platform targeting advanced solid cancers.LinkedInPress Release Series CA LinkedIn post highlighted five positive developments across Scotland's life science and biotech sector over the past two weeks. Causeway Therapeutics presented Phase 2 clinical trial data for a tennis elbow treatment showing significant improvements in pain, function, and tendon structure. Additional companies including BDD (oral drug delivery platform), Swarm Oncology (T-cell therapy partnership), PhytoVenomics (Innovate UK funding recipient), and PhaSER Biomedical (MHRA AI initiative partner) all announced milestones. The author frames these achievements as evidence of Scotland's continued scientific innovation despite broader challenges in the sector.GlobeNewswireSwarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancersSwarm Oncology Ltd., a London-based biotechnology company, announced a research collaboration with a leading US clinic on October 28, 2025, to advance T cell therapies for advanced solid cancers. Under the two-part feasibility study, the clinic will provide patient blood samples and immune response data from cancer vaccine recipients, which Swarm will use to assess T cell responses and potentially manufacture research-scale Swarm-T cell preparations. The collaboration aims to validate Swarm's platform ability to enhance the effectiveness of cancer vaccines and overcome historic limitations of immunotherapy approaches for solid tumors.PR NewswireSwarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm's Innovative T Cell Therapies for Solid CancersSwarm Oncology and Cellex Cell Professionals announced a strategic partnership to advance Swarm's T cell therapies for solid cancers. Cellex will supply cellular starting material, oversee GMP manufacturing, and support regulatory compliance, aiming to accelerate clinical trials in 2026.GlobeNewswireSwarm Oncology Unveils Highly Differentiated, Personalised T Cell Therapy Platform to Significantly Improve Treatment Outcome for Cancer Patients and Appoints Martin Olin as Chief Executive OfficerSwarm Oncology, a biotech developing T cell therapies for solid cancers, appointed Martin Olin as CEO. The company's Swarm-T platform aims to overcome immunotherapy limitations, with over 82% of advanced metastatic cancer patients dying from disease. It expects to advance its first therapeutic candidate into clinical trials within 12-15 months.GlobeNewswireSwarm Oncology Unveils Highly Differentiated, Personalised T Cell Therapy Platform to Significantly Improve Treatment Outcome for Cancer Patients and Appoints Martin Olin as Chief Executive OfficerSwarm Oncology, a biotech developing T cell therapies for solid cancers, appointed Martin Olin as CEO. The company's Swarm-T platform aims to overcome immunotherapy limitations, with over 82% of advanced metastatic cancer patients dying from disease. It expects to advance its first therapeutic candidate into clinical trials within 12-15 months.